ISGF-3γ p48, more commonly known as IRF-9 (Interferon Regulatory Factor 9), is a vital component of the complex that plays a critical role in the interferon-stimulated gene expression pathway. This complex is predominantly known for its role in immune responses, especially in relation to viral infections. Activators of ISGF-3γ p48, therefore, are chemical entities that modulate the activity or expression of IRF-9, facilitating its interaction and subsequent cellular processes. At the molecular level, these activators can function through a range of mechanisms, which may include direct binding to IRF-9, altering its conformation, enhancing its stability, or modulating its interaction with other protein partners. Given the pivotal role of IRF-9 in cellular defense mechanisms, understanding the nature and mechanism of these activators is crucial for the broader understanding of cell biology.
The biochemistry behind ISGF-3γ p48 and its activators is intriguing. The ISGF-3 complex, of which IRF-9 is an integral part, also includes the STAT1 and STAT2 proteins. When cells encounter interferons, this tripartite complex forms and subsequently translocates to the cell nucleus. There, it binds to specific DNA sequences, leading to the transcription of interferon-stimulated genes. Activators of ISGF-3γ p48 could potentially influence any stage of this process, from the formation of the ISGF-3 complex, its translocation, or its DNA-binding efficiency. Unraveling the precise methods through which these activators operate not only offers insight into IRF-9 and the ISGF-3 pathway but also extends our understanding of the intricate regulatory networks that maintain cellular homeostasis and defense.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
A Janus kinase (JAK) inhibitor. By inhibiting JAKs, it can influence the activation status of the ISGF3 pathway. | ||||||
Polyinosinic acid - polycytidylic acid sodium salt, double-stranded | 42424-50-0 | sc-204854 sc-204854A | 10 mg 100 mg | $139.00 $650.00 | 2 | |
A synthetic analog of double-stranded RNA. It can activate RNA sensors like RIG-I and MDA5, leading to downstream effects on the ISGF3 pathway. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $196.00 $651.00 | ||
Another JAK inhibitor, primarily JAK1/JAKIt has been investigated for various conditions, including its role in controlling inflammation in COVID-19 patients, and it would influence the JAK-STAT and ISGF3 pathways. | ||||||
DMXAA | 117570-53-3 | sc-207592 sc-207592A | 5 mg 25 mg | $129.00 $590.00 | 1 | |
A compound known to activate the STING pathway, which can have downstream effects on the ISGF3 pathway. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
A tyrosine kinase inhibitor used for EGFR-mutated non-small cell lung cancer. Some tyrosine kinase inhibitors may have off-target effects on the JAK-STAT pathway. | ||||||
AZD1480 | 935666-88-9 | sc-364735 sc-364735A | 5 mg 50 mg | $122.00 $1051.00 | 11 | |
An inhibitor of JAK1/2, thereby influencing the ISGF3 pathway activation status. |